REG - Physiomics PLC - Physiomics Awarded Follow On Contract by UK Client

PhysiomicsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251215:nRSO5485La&default-theme=true

RNS Number : 5485L  Physiomics PLC  15 December 2025

15 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded Follow On Contract by UK Client

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a follow on contract
with an existing UK based-client.

This new project builds on the contract award announced on 9 May 2025, under
which Physiomics assisted its client in developing a population
Pharmacokinetic (PK) model to inform the design of a Phase 2 clinical study
for a small molecule therapeutic targeting rheumatoid arthritis. As the client
prepares to initiate their clinical trial, this latest contract reflects a
continued commitment to support the project throughout the execution of the
Phase 2 study. Due to timelines associated with patient recruitment and data
generation, this project is not anticipated to commence until 2027. The
extended period between contract signature and project commencement is
attributable to the client's desire to secure key service providers before
initiating the trial. Upon initiation, the project is expected to run for
approximately six months and due to flexibility in the scope of work has a
value between £116K and £169K.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been awarded this new contract and to have the
opportunity to continue supporting our client through their Phase 2 trial.
This offers Physiomics an excellent chance to provide valuable insights that
could guide the development of this Rheumatoid Arthritis asset, while also
allowing us to begin expanding our project pipeline for the next financial
year."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFSVFVLSLIE



            Copyright 2019 Regulatory News Service, all rights reserved